Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement

被引:4
|
作者
Coustal, Cyrille [1 ,2 ]
Goulabchand, Radjiv [2 ,3 ]
Labauge, Pierre [2 ,4 ,5 ]
Guilpain, Philippe [1 ,2 ,6 ]
Carra-Dalliere, Clarisse [4 ]
Januel, Edouard [7 ,8 ,9 ,10 ]
Jeziorski, Eric [2 ,11 ]
Salle, Valery [12 ]
Viallard, Jean-Francois [13 ,14 ]
Boutboul, David [15 ,16 ,17 ]
Fieschi, Claire [15 ,17 ,18 ]
Gobert, Delphine [19 ]
Aladjidi, Nathalie [20 ,21 ,22 ]
Rullier, Patricia [1 ]
Graveleau, Julie [23 ]
Piel-Julian, Marie [24 ]
Suarez, Felipe [25 ,26 ,27 ,28 ]
Neven, Benedicte [28 ,29 ,30 ]
Mahlaoui, Nizar [29 ,31 ]
Ayrignac, Xavier [2 ,4 ,5 ]
机构
[1] Montpellier Univ Hosp, Local Referral Ctr Rare Autoimmune Dis, Dept Internal Med & Multiorgan Dis, Montpellier, France
[2] Univ Montpellier, Montpellier, France
[3] CHU Nimes, Dept Internal Med, Nimes, France
[4] Montpellier Univ Hosp, Dept Neurol, Montpellier, France
[5] INSERM, INM, Montpellier, France
[6] INSERM, U1183, Inst Regenerat Med & Biotherapy, Montpellier, France
[7] Sorbonne Univ, Paris, France
[8] Inst Pierre Louis Epidemiol & Sante Publ, Paris, France
[9] Hop La Pitie Salpetriere, AP HP, Dept Sante Publ, Paris, France
[10] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France
[11] Montpellier Univ Hosp, Dept Pediat, Montpellier, France
[12] Amiens Univ Med Ctr, Dept Internal Med, Amiens, France
[13] Bordeaux Univ Hosp Ctr, Dept Internal Med, Bordeaux, France
[14] Hop Haut Leveque, Pessac, France
[15] Natl Reference Ctr Castleman Dis, Dept Clin Immunol, Paris, France
[16] Hop St Louis, AP HP, INSERM, CRI,UMR 1149, Paris, France
[17] Univ Paris Diderot, Paris, France
[18] Hop St Louis, Ctr Hayem, INSERM, U1126, Paris, France
[19] Hop St Antoine, AP HP, Dept Internal Med, Paris, France
[20] Bordeaux Univ Hosp, Pediat Hematol Oncol Unit, Bordeaux, France
[21] INSERM, CIC 1401, Plurithemat CIC CICP, Bordeaux, France
[22] Ctr Reference Natl Cytopenies Autoimmunes Enfant, Bordeaux, France
[23] St Nazaire Hosp, Dept Internal Med, Toulouse, France
[24] Purpan Univ Hosp, Dept Internal Med, Toulouse, France
[25] Necker Enfants Malades Univ Hosp, AP HP, Dept Hematol, Paris, France
[26] INSERM, UMR 1163, Paris, France
[27] CNRS, ERL 8254, Paris, France
[28] Descartes Univ, Imagine Inst, Paris, France
[29] Hop Necker Enfants Malad, AP HP, Pediat Hematol Immuol & Rheumatol Dept, Paris, France
[30] Imagine Inst, INSERM, UMR 1163, Lab Immunogenet Pediat Autoimmun, Paris, France
[31] Necker Enfants Malades Univ Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France
关键词
MULTIPLE-SCLEROSIS;
D O I
10.1212/WNL.0000000000207609
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives CTLA4 deficiency (CTLA4d) is a disease with multisystem autoimmune features, including neurologic manifestations. We aimed to describe neurologic involvement in these patients. Methods We performed a cross-sectional observational study using the French Reference Centre for Primary Immunodeficiencies (CEREDIH) registry plus a surveillance in national society networks. Participants with confirmed CTLA4d and neurologic involvement were included. Clinical, laboratory, and radiologic features were collected, as well as treatments. Available MRI was double-reviewed. Results Among 70 patients with CTLA4d, 13 patients (21%) had neurologic involvement. Neurologic symptoms began at a median age of 18 [15-45] years, mostly occurring after systemic manifestations (median delay: 8.5 [4.5-10.5] years). Main symptoms included headaches, focal deficit (54% each), and seizures (38%). MRI detected at least 1 large contrast-enhancing lesion in 8 patients. Lesions reminiscent of multiple sclerosis lesions were found in 6 patients. Cerebellar (6 patients) and large spinal cord lesions (3 patients) were common. Ten patients were treated with abatacept, of whom 9 (90%) showed good clinical and radiologic response. Discussion Neurologic involvement is common among patients with CTLA4d. Despite its rarity, and considering the suspected efficacy of abatacept, neurologists should be aware of the characteristics of CTLA4d neurologic involvement.
引用
收藏
页码:E1560 / E1566
页数:7
相关论文
共 50 条
  • [41] Circulating Soluble CTLA4 (sCTLA4) Is Elevated in Patients With Breast Cancer
    Erfani, Nasrollah
    Razmkhah, Mahbobeh
    Ghaderi, Abbas
    CANCER INVESTIGATION, 2010, 28 (08) : 828 - 832
  • [42] Clinical trial of therapeutic blockade of CTLA4 with ipilimumab in patients with relapse of malignancy following allogeneic hematopoietic transplantation
    Bashey, Asad
    Medina, Bridget
    Corringham, Sue
    Pasek, Mildred
    Carrier, Ewa
    Vrooman, Linda
    Streicher, Howard
    Lowy, Israel
    Solomon, Scott W.
    Morris, Lawrence E.
    Holland, Kent
    Mason, James R.
    Soiffer, Robert J.
    Ball, Edward D.
    BLOOD, 2007, 110 (11) : 491A - 491A
  • [43] Psoriatic arthritis in Israel - A clinical, immunologic and radiologic study of 97 patients
    Eder, L.
    Rosner, I.
    Rosenbaum, M.
    Feld, J.
    Rimar, D.
    Zisman, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 214 - 214
  • [44] CTLA4 gene polymorphisms in Dutch and Chinese patients with inflammatory bowel disease
    Xia, B
    Crusius, JBA
    Wu, J
    Zwiers, A
    van Bodegraven, AA
    Peña, AS
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (11) : 1296 - 1300
  • [45] Neurological features of CTLA4 insufficiency: a nationwide study of a poorly understood neuroinflammatory genetic disorder
    Coustal, C.
    Goulabchand, R.
    Labauge, P.
    Guilpain, P.
    Carra-Dalliere, C.
    Januel, E.
    Jeziorski, E.
    Salle, V.
    Viallard, J. -F.
    Boutboul, D.
    Fieschi, C.
    Gobert, D.
    Rullier, P.
    Graveleau, J.
    Piel-Julian, M. -L.
    Suarez, F.
    Neven, B.
    Mahlaoui, N.
    Ayrignac, X.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 409 - 410
  • [46] CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients
    Vaddi, Prasanna Kumar
    Osborne, Douglas Grant
    Nicklawsky, Andrew
    Williams, Nazanin K.
    Menon, Dinoop Ravindran
    Smith, Derek
    Mayer, Jonathan
    Reid, Anna
    Domenico, Joanne
    Nguyen, Giang Huong
    Robinson, William A.
    Ziman, Melanie
    Gao, Dexiang
    Zhai, Zili
    Fujita, Mayumi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] CTLA4 1661 A/G polymorphisms in North Indian Celiac disease patients
    Palhora, Shilpa
    Saikia, Biman
    Arora, Sunil
    Thapa, B.
    Lal, Sadhna
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [48] Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report
    Mazzoni, Marta
    Dell'Orso, Gianluca
    Grossi, Alice
    Ceccherini, Isabella
    Viola, Stefania
    Terranova, Paola
    Micalizzi, Concetta
    Guardo, Daniela
    Massaccesi, Erika
    Palmisani, Elena
    Calvillo, Michaela
    Fioredda, Francesca
    Malattia, Clara
    Dufour, Carlo
    Ravelli, Angelo
    Miano, Maurizio
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (08) : E1168 - E1172
  • [49] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
    Goltz, Diane
    Gevensleben, Heidrun
    Vogt, Timo J.
    Dietrich, Joern
    Golletz, Carsten
    Bootz, Friedrich
    Kristiansen, Glen
    Landsberg, Jennifer
    Dietrich, Dimo
    JCI INSIGHT, 2018, 3 (13):
  • [50] Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
    Ribas, Antoni
    Comin-Anduix, Begona
    Chmielowski, Bartosz
    Jalil, Jason
    de la Rocha, Pilar
    McCannel, Tara A.
    Ochoa, Maria Teresa
    Seja, Elizabeth
    Villanueva, Arturo
    Oseguera, Denise K.
    Straatsma, Bradley R.
    Cochran, Alistair J.
    Glaspy, John A.
    Hui, Liu
    Marincola, Francesco M.
    Wang, Ena
    Economou, James S.
    Gomez-Navarro, Jesus
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6267 - 6276